Exploiting Multivalency in Drug DesignMUNOZ-TORRERO, Diego.Current pharmaceutical design (Print). 2009, Vol 15, Num 6, issn 1381-6128, 146 p.Serial Issue

Alzheimer drug design based on the amyloid hypothesisMUNOZ-TORRERO, Diego; CAMPS, Pelayo.Current pharmaceutical design. 2006, Vol 12, Num 33, issn 1381-6128, 129 p.Serial Issue

Designing Multiple Ligands : Medicinal Chemistry Strategies and ChallengesMORPHY, Richard; RANKOVIC, Zoran.Current pharmaceutical design (Print). 2009, Vol 15, Num 6, pp 587-600, issn 1381-6128, 14 p.Article

Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitorsCASTRO, Ana; MARTINEZ, Ana.Current pharmaceutical design. 2006, Vol 12, Num 33, pp 4377-4387, issn 1381-6128, 11 p.Article

Molecular and biochemical features in Alzheimer's diseasePALLAS, Mercè; CAMINS, Antoni.Current pharmaceutical design. 2006, Vol 12, Num 33, pp 4389-4408, issn 1381-6128, 20 p.Article

Novel Classes of Dimer Antitumour Drug CandidatesCHOW, Larry M. C; TAK HANG CHAN.Current pharmaceutical design (Print). 2009, Vol 15, Num 6, pp 659-674, issn 1381-6128, 16 p.Article

Multivalent-Based Drug Design Applied to Serotonin 5-HT₄ Receptor OligomersLEZOUALC'H, Frank; JOCKERS, Ralf; BERQUE-BESTEL, Isabelle et al.Current pharmaceutical design (Print). 2009, Vol 15, Num 6, pp 719-729, issn 1381-6128, 11 p.Article

Pharmacodynamic Hybrids Coupling Established Cardiovascular Mechanisms of Action with Additional Nitric Oxide Releasing PropertiesMARTELLI, Alma; BRESCHI, Maria Cristina; CALDERONE, Vincenzo et al.Current pharmaceutical design (Print). 2009, Vol 15, Num 6, pp 614-636, issn 1381-6128, 23 p.Article

Design of Multivalent Ligand Targeting G-Protein-Coupled ReceptorsZHILI LIU; JING ZHANG; AO ZHANG et al.Current pharmaceutical design (Print). 2009, Vol 15, Num 6, pp 682-718, issn 1381-6128, 37 p.Article

Multivalent & Multifunctional Ligands to β-AmyloidKIM, Youngsoo; JI HOON LEE; RYU, Jiyeon et al.Current pharmaceutical design (Print). 2009, Vol 15, Num 6, pp 637-658, issn 1381-6128, 22 p.Article

Selective modulation of Aβ42 production in Alzheimer's disease : Non-steroidal anti-inflammatory drugs and beyondLEUCHTENBERGER, Stefanie; BEHER, Dirk; WEGGEN, Sascha et al.Current pharmaceutical design. 2006, Vol 12, Num 33, pp 4337-4355, issn 1381-6128, 19 p.Article

Vaccine development for Alzheimer's diseaseDASILVA, Kevin A; AUBERT, Isabelle; MCLAURIN, Joanne et al.Current pharmaceutical design. 2006, Vol 12, Num 33, pp 4283-4293, issn 1381-6128, 11 p.Article

Views on amyloid hypothesis and secretase inhibitors for treating Alzheimer's disease : Progress and problemsNGUYEN, Jeffrey-Tri; YAMANI, Abdellah; KISO, Yoshiaki et al.Current pharmaceutical design. 2006, Vol 12, Num 33, pp 4295-4312, issn 1381-6128, 18 p.Article

Synthesis and pharmacological evaluation of huprine-tacrine heterodimers : Subnanomolar dual binding site acetylcholinesterase inhibitorsCAMPS, Pelayo; FORMOSA, Xavier; MUNOZ-TORRERO, Diego et al.Journal of medicinal chemistry (Print). 2005, Vol 48, Num 6, pp 1701-1704, issn 0022-2623, 4 p.Article

Designer Peptides : Learning from NatureSHRIVASTAVA, A; NUNN, A. D; TWEEDLE, M. F et al.Current pharmaceutical design (Print). 2009, Vol 15, Num 6, pp 675-681, issn 1381-6128, 7 p.Article

The development of preventives and therapeutics for Alzheimer's disease that inhibit the formation of β-amyloid fibrils (fAβ), as well as destabilize preformed fAβONO, Kenjiro; NAIKI, Hironobu; YAMADA, Masahito et al.Current pharmaceutical design. 2006, Vol 12, Num 33, pp 4357-4375, issn 1381-6128, 19 p.Article

Synthesis, in vitro pharmacology, and molecular modeling of syn-huprines as acetylcholinesterase inhibitorsCAMPS, Pelayo; GOMEZ, Elena; MUNOZ-TORRERO, Diego et al.Journal of medicinal chemistry (Print). 2001, Vol 44, Num 26, pp 4733-4736, issn 0022-2623Article

The pharmacology of novel acetylcholinesterase inhibitors, (±)-huprines Y and X, on the Torpedo electric organROS, Esteve; ALEU, Jordi; GOMEZ DE ARANDA, Inmaculada et al.European journal of pharmacology. 2001, Vol 421, Num 2, pp 77-84, issn 0014-2999Article

MTDL Design Strategy in the Context of Alzheimer's Disease : From Lipocrine to Memoquin and BeyondBOLOGNESI, M. L; ROSINI, M; ANDRISANO, V et al.Current pharmaceutical design (Print). 2009, Vol 15, Num 6, pp 601-613, issn 1381-6128, 13 p.Article

Gamma-secretase as a pharmacological target in Alzheimer disease research : When, why and how?ZIANI-CHERIF, Chewki; MOSTEFA-KARA, Bachir; BRIXI-GORMAT, Fatima Z et al.Current pharmaceutical design. 2006, Vol 12, Num 33, pp 4313-4335, issn 1381-6128, 23 p.Article

Characterisation of the anticholinesterase activity of two new tacrine-huperzine A hybridsDEL MAR ALCALA, Maria; VIVAS, Nuria Maria; HOSPITAL, Susana et al.Neuropharmacology. 2003, Vol 44, Num 6, pp 749-755, issn 0028-3908, 7 p.Article

Binding of 13-amidohuprines to acetylcholinesterase : Exploring the ligand-induced conformational change of the gly117-gly118 peptide bond in the oxyanion holeCAMPS, Pelayo; GOMEZ, Elena; MUNOZ-TORRERO, Diego et al.Journal of medicinal chemistry (Print). 2006, Vol 49, Num 23, pp 6833-6840, issn 0022-2623, 8 p.Article

Pyrano[3,2-c]quinoline―6-Chlorotacrine Hybrids as a Novel Family of Acetylchotinesterase-and β-Amyloid-Directed Anti-Alzheimer CompoundsCAMPS, Pelayo; FORMOSA, Xavier; BARTOLINI, Manuela et al.Journal of medicinal chemistry (Print). 2009, Vol 52, Num 17, pp 5365-5379, issn 0022-2623, 15 p.Article

New tacrine-huperzine A hybrids (huprines) : Highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's diseaseCAMPS, Pelayo; EL ACHAB, Rachid; MORRAL, Jordi et al.Journal of medicinal chemistry (Print). 2000, Vol 43, Num 24, pp 4657-4666, issn 0022-2623Article

Novel Donepezil-Based Inhibitors of Acetyl-and Butyrylcholinesterase and Acetylcholinesterase-Induced β-Amyloid AggregationCAMPS, Pelayo; FORMOSA, Xavier; PALLAS, Mercè et al.Journal of medicinal chemistry (Print). 2008, Vol 51, Num 12, pp 3588-3598, issn 0022-2623, 11 p.Article